We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

  • Ashish M. Kamat1Email author,
  • Joaquim Bellmunt2,
  • Matthew D. Galsky3,
  • Badrinath R. Konety4,
  • Donald L. Lamm5,
  • David Langham6,
  • Cheryl T. Lee7,
  • Matthew I. Milowsky8,
  • Michael A. O’Donnell9,
  • Peter H. O’Donnell10,
  • Daniel P. Petrylak11,
  • Padmanee Sharma12,
  • Eila C. Skinner13,
  • Guru Sonpavde14,
  • John A. TaylorIII15,
  • Prasanth Abraham16 and
  • Jonathan E. Rosenberg17
Journal for ImmunoTherapy of Cancer20175:80

https://doi.org/10.1186/s40425-017-0280-z

Received: 30 August 2017

Accepted: 31 August 2017

Published: 28 September 2017

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Erratum

After the publication of the article [1], the treatment algorithm for advanced/metastatic bladder cancer in Fig. 3 was updated to reflect the current use of immunotherapy in this setting. The correct Fig. 3 can be seen here and the original article has been updated to reflect this change.
Fig. 3

All of the treatment options shown may be appropriate. The selection of therapy should be individualized based on patient eligibility and the availability of therapy, at the discretion of the treating physician. These algorithms represent the consensus recommendations of the Task Force. (1) Atezolizumab and pembrolizumab are FDA approved for patients with metastatic urothelial carcinoma who are ineligible to receive cisplatin. (2) Atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab are FDA approved for advanced disease that has worsened on platinum containing regimens or within 12 months of receiving a platinum-containing regimen before (neoadjuvant) or after surgery (adjuvant). Abbreviations: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DDMVAC)

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
University of Texas MD Anderson Cancer Center
(2)
Dana-Farber Cancer Institute
(3)
Tisch Cancer Institute at Mount Sinai Medical Center
(4)
University of Minnesota
(5)
BCG Oncology
(6)
Bladder Cancer Advocacy Network, North Carolina Triangle Chapter
(7)
The Ohio State University Wexner Medical Center
(8)
University of North Carolina
(9)
University of Iowa
(10)
University of Chicago
(11)
Yale Cancer Center
(12)
University of Texas MD Anderson Cancer Center
(13)
Stanford University
(14)
University of Alabama
(15)
University of Kansas Cancer Center
(16)
University of Texas MD Anderson Cancer Center
(17)
Memorial Sloan Kettering Cancer Center

Reference

  1. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Journal for Immunotherapy of Cancer. 2017;5:68. https://doi.org/10.1186/s40425-017-0271-0 View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement